Hcw Biologics Inc. Stock Price, News & Analysis

HCW Biologics has been granted U.S. Patent No. 11,518,792 for its novel multi-function fusion immunotherapeutic, HCW9218, which targets TGF-β and stimulates immune cells. This patent builds upon an earlier patent, enhancing the company's intellectual property portfolio around its TOBI™ platform. HCW9218 is currently in early-stage clinical trials for chemo-refractory solid tumors, including advanced pancreatic cancer. The company aims to address chronic inflammation linked to age-related diseases through innovative therapies.

HCW Biologics (NASDAQ: HCWB) announced data from an ongoing Phase 1 trial of HCW9218, targeting chemo-refractory solid tumors. The trial, conducted by the Masonic Cancer Center, University of Minnesota, aims to evaluate the safety and efficacy of HCW9218, a bifunctional TGF-β antagonist designed to stimulate immune responses while inhibiting tumor growth. The presentation at the Society for Immunotherapy of Cancer meeting will detail the absence of mucosal bleeding incidents linked to the treatment. HCW Biologics has also initiated a Phase 1b/2 trial specifically for pancreatic cancer.

HCW Biologics Inc. (NASDAQ: HCWB) reported its Q3 2022 financial results, highlighting $1.8 million in revenue, a significant increase from $0 in Q3 2021. The company has $35.9 million in cash and equivalents, projected to fund operations through 2023. Notably, three clinical sites have been opened for the HCW9218 trial on advanced pancreatic cancer, with the first patient dosed on October 17, 2022. Research expenses remained stable while administrative costs rose 23%. The net loss for Q3 2022 decreased by 5% to $3.9 million compared to the same period last year.

HCW Biologics Inc. (NASDAQ: HCWB) reported financial results for Q2 2022, revealing revenues of $454,000 against no revenues in Q2 2021. The company has made strides with its lead product candidate HCW9218 entering clinical trials, and they anticipate starting a pancreatic cancer trial soon. They are also moving forward with their HCW9302 candidate, supported by preclinical data and a forthcoming pivotal publication. HCW Biologics is purchasing a $10 million facility in Miramar, Florida, to enhance manufacturing capabilities, ensuring control over its supply chain.

HCW Biologics Inc. (NASDAQ: HCWB) has been granted U.S. Patent 11,401,324 for its lead product candidate, HCW9302, which is aimed at addressing inflammation-related diseases through the activation of regulatory T cells. This patent secures intellectual property for a single-chain, IL-2-based fusion protein that has shown promise in preclinical studies. The company is also advancing IND-enabling studies for an autoimmune disorder. This milestone is part of HCW Biologics' broader patent strategy surrounding its TOBI™ platform, which focuses on novel immunotherapies.

HCW Biologics Inc. (NASDAQ: HCWB) announced that Dr. Hing C. Wong, Founder and CEO, will present at the H.C. Wainwright Annual Global Life Sciences Conference on May 25, 2022. The presentation will cover an update on the clinical trial of HCW9218 for advanced solid tumors and the company’s immunotherapy strategy aimed at improving cancer treatment outcomes. The Masonic Cancer Center, University of Minnesota, has initiated a Phase 1 trial for HCW9218, with FDA clearance for a Phase 1b trial in advanced pancreatic cancer. The presentation will be available on the company's investor relations website.

HCW Biologics Inc. (NASDAQ: HCWB) reported its financial results for Q1 2022, showing revenues of $3.1 million, a significant increase from no revenues in Q1 2021. The company has a strong cash position with $18.1 million in cash and equivalents, sufficient to fund operations through 2023. R&D expenses decreased by 22% to $1.8 million, while G&A expenses rose by 73% to $1.9 million due to increased salaries and stock-based compensation. The net loss narrowed to $2.1 million, reflecting improved financial management.

HCW Biologics (NASDAQ: HCWB) presented its innovative immunotherapeutics at the 105th Annual Meeting of the American Association of Immunologists. The company's TOBI™ discovery platform allows for the creation of cytokine-based fusion proteins aimed at activating memory-like NK cells and expanding regulatory T cells for diverse therapeutic applications. These advancements potentially enhance adoptive cell therapy, eliminating the need for feeder cells and magnetic beads, thereby improving scalability and consistency in treatments for cancer and autoimmune diseases.

HCW Biologics (NASDAQ: HCWB) announced the presentation of new preclinical data for its investigational drug, HCW9218, at the CEB-2022 conference. The data demonstrates HCW9218's potential to enhance chemotherapy's anti-tumor effects while reducing harmful side effects linked to therapy-induced senescence (TIS). This aligns with the company's goal to address age-related diseases by disrupting chronic inflammation. Dr. Hing C. Wong, founder and CEO, emphasized the dual role of HCW9218 as a senolytic agent, beneficial for both cancer treatment and overall health span improvement.